Inhibikase Therapeutics IncNASDAQ:IKT
- LAST PRICE1.3700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4200/ 2
- Ask / Lots1.4800/ 1
- Open / Previous Close1.9600 / 1.3700
- Day Range
- 52 Week Range
- Volume369,205
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IKT |
|---|---|---|
| 09:32 ET | 5259 | 1.95 |
| 09:34 ET | 1283 | 1.9 |
| 09:36 ET | 18634 | 1.6 |
| 09:38 ET | 16523 | 1.73 |
| 09:39 ET | 200 | 1.72 |
| 09:41 ET | 833 | 1.6505 |
| 09:43 ET | 3500 | 1.62 |
| 09:45 ET | 1542 | 1.69 |
| 09:48 ET | 2567 | 1.7198 |
| 09:50 ET | 6125 | 1.74 |
| 09:52 ET | 2707 | 1.74 |
| 09:54 ET | 11239 | 1.7399 |
| 09:56 ET | 964 | 1.65 |
| 09:57 ET | 500 | 1.65 |
| 09:59 ET | 1000 | 1.63 |
| 10:01 ET | 500 | 1.63 |
| 10:03 ET | 400 | 1.63 |
| 10:06 ET | 1290 | 1.66 |
| 10:08 ET | 1225 | 1.62 |
| 10:10 ET | 200 | 1.62 |
| 10:12 ET | 400 | 1.63 |
| 10:14 ET | 750 | 1.64 |
| 10:15 ET | 700 | 1.61 |
| 10:17 ET | 1500 | 1.64 |
| 10:19 ET | 207 | 1.61 |
| 10:21 ET | 100 | 1.62 |
| 10:24 ET | 300 | 1.61 |
| 10:26 ET | 1450 | 1.61 |
| 10:28 ET | 8984 | 1.61 |
| 10:30 ET | 2899 | 1.6101 |
| 10:32 ET | 1100 | 1.6199 |
| 10:33 ET | 400 | 1.61 |
| 10:35 ET | 400 | 1.61 |
| 10:37 ET | 576 | 1.61 |
| 10:39 ET | 2258 | 1.56 |
| 10:42 ET | 100 | 1.56 |
| 10:44 ET | 1084 | 1.55 |
| 10:46 ET | 164 | 1.54 |
| 10:48 ET | 13801 | 1.48 |
| 10:50 ET | 2550 | 1.51 |
| 10:51 ET | 8898 | 1.505 |
| 10:53 ET | 800 | 1.53 |
| 10:55 ET | 863 | 1.56 |
| 10:57 ET | 3700 | 1.6199 |
| 11:00 ET | 300 | 1.59 |
| 11:02 ET | 11929 | 1.582 |
| 11:04 ET | 1553 | 1.64 |
| 11:06 ET | 4350 | 1.63 |
| 11:08 ET | 4608 | 1.6499 |
| 11:09 ET | 554 | 1.62 |
| 11:11 ET | 800 | 1.61 |
| 11:13 ET | 100 | 1.61 |
| 11:15 ET | 926 | 1.61 |
| 11:18 ET | 1100 | 1.6314 |
| 11:20 ET | 300 | 1.61 |
| 11:22 ET | 1700 | 1.61 |
| 11:24 ET | 200 | 1.61 |
| 11:26 ET | 3343 | 1.6 |
| 11:27 ET | 600 | 1.56 |
| 11:29 ET | 400 | 1.55 |
| 11:31 ET | 425 | 1.5999 |
| 11:33 ET | 400 | 1.55 |
| 11:36 ET | 200 | 1.55 |
| 11:38 ET | 200 | 1.52 |
| 11:40 ET | 400 | 1.52 |
| 11:42 ET | 300 | 1.55 |
| 11:44 ET | 300 | 1.52 |
| 11:45 ET | 100 | 1.52 |
| 11:47 ET | 500 | 1.52 |
| 11:49 ET | 300 | 1.52 |
| 11:51 ET | 400 | 1.52 |
| 11:54 ET | 300 | 1.52 |
| 11:56 ET | 400 | 1.52 |
| 11:58 ET | 1600 | 1.52 |
| 12:00 ET | 500 | 1.53 |
| 12:02 ET | 300 | 1.53 |
| 12:03 ET | 400 | 1.53 |
| 12:05 ET | 300 | 1.53 |
| 12:07 ET | 486 | 1.53 |
| 12:09 ET | 1300 | 1.53 |
| 12:12 ET | 500 | 1.55 |
| 12:14 ET | 500 | 1.56 |
| 12:16 ET | 200 | 1.55 |
| 12:18 ET | 300 | 1.55 |
| 12:20 ET | 100 | 1.53 |
| 12:21 ET | 432 | 1.5729 |
| 12:23 ET | 400 | 1.53 |
| 12:25 ET | 300 | 1.54 |
| 12:27 ET | 350 | 1.52 |
| 12:30 ET | 8658 | 1.54 |
| 12:32 ET | 400 | 1.49 |
| 12:34 ET | 400 | 1.49 |
| 12:36 ET | 499 | 1.5299 |
| 12:38 ET | 500 | 1.5 |
| 12:39 ET | 300 | 1.47 |
| 12:41 ET | 300 | 1.51 |
| 12:43 ET | 1725 | 1.51 |
| 12:45 ET | 400 | 1.51 |
| 12:48 ET | 100 | 1.51 |
| 12:50 ET | 400 | 1.5 |
| 12:52 ET | 200 | 1.5 |
| 12:54 ET | 300 | 1.5 |
| 12:56 ET | 648 | 1.47 |
| 12:57 ET | 9900 | 1.4997 |
| 12:59 ET | 100 | 1.47 |
| 01:01 ET | 10600 | 1.47 |
| 01:03 ET | 272 | 1.4998 |
| 01:06 ET | 2300 | 1.53 |
| 01:08 ET | 300 | 1.55 |
| 01:10 ET | 17550 | 1.59 |
| 01:12 ET | 100 | 1.59 |
| 01:14 ET | 500 | 1.585 |
| 01:15 ET | 300 | 1.51 |
| 01:17 ET | 10100 | 1.5 |
| 01:19 ET | 10697 | 1.55 |
| 01:24 ET | 200 | 1.51 |
| 01:26 ET | 1000 | 1.5099 |
| 01:28 ET | 100 | 1.53 |
| 01:30 ET | 300 | 1.5201 |
| 01:32 ET | 200 | 1.54 |
| 01:33 ET | 1000 | 1.5491 |
| 01:42 ET | 4050 | 1.55 |
| 01:44 ET | 600 | 1.55 |
| 01:50 ET | 1500 | 1.57 |
| 01:51 ET | 200 | 1.55 |
| 01:55 ET | 300 | 1.571 |
| 01:57 ET | 500 | 1.55 |
| 02:00 ET | 200 | 1.551 |
| 02:06 ET | 100 | 1.551 |
| 02:08 ET | 5175 | 1.6 |
| 02:09 ET | 400 | 1.6 |
| 02:11 ET | 200 | 1.6 |
| 02:13 ET | 600 | 1.6 |
| 02:15 ET | 400 | 1.6 |
| 02:18 ET | 5463 | 1.6 |
| 02:20 ET | 200 | 1.6 |
| 02:22 ET | 583 | 1.6 |
| 02:24 ET | 10509 | 1.5701 |
| 02:26 ET | 398 | 1.57 |
| 02:27 ET | 818 | 1.55 |
| 02:29 ET | 400 | 1.55 |
| 02:31 ET | 300 | 1.55 |
| 02:33 ET | 400 | 1.55 |
| 02:36 ET | 2500 | 1.55 |
| 02:44 ET | 100 | 1.53 |
| 02:45 ET | 400 | 1.53 |
| 02:47 ET | 400 | 1.51 |
| 02:49 ET | 400 | 1.5 |
| 02:51 ET | 600 | 1.5 |
| 02:54 ET | 400 | 1.5 |
| 02:56 ET | 600 | 1.5 |
| 02:58 ET | 600 | 1.5 |
| 03:00 ET | 600 | 1.5 |
| 03:02 ET | 1000 | 1.51 |
| 03:03 ET | 600 | 1.5 |
| 03:05 ET | 600 | 1.5 |
| 03:07 ET | 3100 | 1.5 |
| 03:09 ET | 1626 | 1.5 |
| 03:12 ET | 800 | 1.5 |
| 03:14 ET | 13605 | 1.4199 |
| 03:16 ET | 4086 | 1.4 |
| 03:18 ET | 500 | 1.4 |
| 03:20 ET | 100 | 1.41 |
| 03:21 ET | 200 | 1.41 |
| 03:25 ET | 400 | 1.4199 |
| 03:27 ET | 400 | 1.4 |
| 03:30 ET | 879 | 1.4 |
| 03:32 ET | 400 | 1.4 |
| 03:34 ET | 400 | 1.4 |
| 03:36 ET | 885 | 1.37 |
| 03:38 ET | 400 | 1.38 |
| 03:39 ET | 400 | 1.35 |
| 03:41 ET | 4350 | 1.3799 |
| 03:43 ET | 369 | 1.38 |
| 03:45 ET | 600 | 1.39 |
| 03:48 ET | 6631 | 1.41 |
| 03:50 ET | 3400 | 1.37 |
| 03:52 ET | 1200 | 1.36 |
| 03:54 ET | 1100 | 1.36 |
| 03:56 ET | 1400 | 1.361 |
| 03:57 ET | 2600 | 1.361 |
| 03:59 ET | 3781 | 1.37 |
Apr 18, 2024
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs, from 4:30PM ET on Thursday Apr 18, 2024 by Dow Jones
4:30PM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 3, 2024
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension, from 8:05AM ET on Wednesday Apr 03, 2024 by Dow Jones
8:05AM ET on Wednesday Apr 03, 2024 by Dow Jones
Mar 27, 2024
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity, from 4:15PM ET on Wednesday Mar 27, 2024 by Dow Jones
4:15PM ET on Wednesday Mar 27, 2024 by Dow JonesPress Release: Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity, from 4:15PM ET on Wednesday Mar 27, 2024 by Dow Jones
4:15PM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibikase Therapeutics Inc | 13.2M | -0.4x | --- |
Check Cap Ltd | 13.2M | -0.8x | --- |
Alterity Therapeutics Ltd | 20.2M | -1.1x | --- |
NanoViricides Inc | 13.0M | -1.4x | --- |
X T L Biopharmaceuticals Ltd | 13.0M | -5.2x | --- |
Kiora Pharmaceuticals Inc | 12.9M | -0.2x | --- |
Company Information
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Contact Information
- Headquarters
- 3350 Riverwood Parkway Se, Suite 1900ATLANTA, GA, United States 30339
- Phone
- 678-392-3419
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Milton Werner
- Chief Financial Officer
- Garth Lees-Rolfe
- Independent Director
- Dennis Berman
- Independent Director
- Gisele Dion
- Independent Director
- Roy Freeman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.2M |
|---|---|
Revenue (TTM) | $260.5K |
Shares Outstanding | 6.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.16 |
EPS | $-3.62 |
Book Value | $1.77 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 50.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,712.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
